Alamar Biosciences, Inc. cash flow to debt ratio of -129.26% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Alamar Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Alamar Biosciences, Inc.'s return on equity of 428.55%, is higher than 15.00%, indicating good performance

Alamar Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Alamar Biosciences, Inc. has insufficient public price history to evaluate earnings stability.

Alamar Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Alamar Biosciences, Inc. has negative free cash flow, indicating cash burn

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

ROIC -7.08% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Alamar Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Alamar Biosciences, Inc. has insufficient public price history to evaluate revenue consistency.

Alamar Biosciences, Inc. has insufficient public price history to evaluate ROE consistency.

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alamar Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Alamar Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Alamar Biosciences, Inc. has insufficient data to evaluate this check.

Alamar Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alamar Biosciences, Inc. has a price-to-book ratio of 31.84x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Alamar Biosciences, Inc. has a price-to-sales ratio of 179.65x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue